Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A rare case of PAPASH syndrome with a NOD2 mutation.

JAAD case reports·2026

Same author

Extensive Subcutaneous Fat Necrosis of the Newborn Diagnosed by Minimally Invasive Ultrasound in a NICU Setting.

Pediatric dermatology·2026

Same author

Unusual recurrent nevi: To use or not to use reflectance confocal microscopy.

JAAD case reports·2026

Same author

Prospective Single-Site Open-label Study Assessing Safety and Efficacy of Poly-L-Lactic Acid for Temple Volume Loss.

Journal of drugs in dermatology : JDD·2026

Same author

Navigating Melanoma In Situ in the Age of Overdiagnosis.

JAMA dermatology·2025

Same author

Exploring the Scope of Melanoma Educational Content on Instagram

Journal of drugs in dermatology : JDD·2025

Same journal

The Impact of Chronic Spontaneous Urticaria on Sleep-A Systematic Review.

Dermatology and therapy·2026

Same journal

Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy.

Dermatology and therapy·2026

Same journal

Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis.

Dermatology and therapy·2026

Same journal

Letter to the Editor Regarding "Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis".

Dermatology and therapy·2026

Same journal

Correction: Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity in Adults in Taiwan: A Cross-sectional Survey.

Dermatology and therapy·2026

Same journal

A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'".

Dermatology and therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 29, 2025

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

CDKN2A Mutation: A Patient's and Physician's Experience.

Yaelle Shaked^1,2, Alyssa Swearingen^1,3, Tracey N Liebman⁴

¹Ronald O. Perelman Department of Dermatology, NYU Langone Health, New York University Grossman School of Medicine, 240 E 38th St, 11th Floor, New York, NY, 10016, USA.

Dermatology and Therapy

|February 8, 2025

Summary

This summary is machine-generated.

The CDKN2A mutation poses significant risks, particularly for familial melanoma patients. Early detection through genetic testing and regular skin surveillance is crucial for managing this hereditary cancer risk.

Keywords:

CDKN2A Dermatological surveillance Early detection Guidelines Melanoma Pancreatic cancer Self-skin exam Skin awareness

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter

Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter

Published on: March 31, 2022

Related Experiment Videos

Last Updated: May 29, 2025

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter

Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter

Published on: March 31, 2022

Area of Science:

Genetics
Oncology
Dermatology

Background:

The article explores the patient and physician viewpoints on the CDKN2A mutation.
It details a patient's personal journey, including the reasons for genetic testing and the diagnosis's impact on his family.

Discussion:

The clinical significance of the CDKN2A mutation and current testing protocols are examined.
The narrative emphasizes the importance of identifying high-risk individuals with familial melanomas.

Key Insights:

Patient experiences offer a personal perspective on living with a CDKN2A mutation diagnosis.
Understanding the psychological and familial impact is vital for comprehensive care.

Outlook:

Routine dermatological surveillance is recommended for individuals at high risk.
Increased awareness and education are needed for effective management of CDKN2A-related conditions.